# EF-15 (NCT00749346)

> NovoTTF-100L in Combination With Pemetrexed (Alimta®) for Advanced Non-small Cell Lung Cancer

No report yet. It can be ordered.

- Drugs tested: none (the trial tests a strategy, not a drug)
- Indication: advanced non-small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT00749346
- Phase: PHASE1, PHASE2
- Status: COMPLETED
- Sponsor: NovoCure Ltd.
- Conditions: Non-small Cell Lung Cancer; NSCLC
- Interventions: NovoTTF-100L
- Enrollment: 42
- Primary outcome: Device related toxicity

## Indexed commentary on EF-15 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 podcast episodes
- 1 post on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=ef-15-nct00749346